Methods and compositions for the treatment of polycystic ovary syndrome.

Composition comprising a GLP-1 molecule selected from GLP-1 (1-37) (SEQ ID NO: 1), GLP-1 (1-36) NH2 (SEQ ID NO: 2), GLP -1 (7-37) (SEQ ID NO: 3), GLP-1 (7-36) NH2 (SEQ ID NO: 4), exendin-3 (SEQ ID NO: 7), exendin -4 (SEQ ID NO: 9) or biologically active variant present more than 90% sequence identity with any of SEQ ID 1 to 4, for use in treating a patient suffering from polycystic ovarian syndrome (PCOS ) - in which the patient has at least one symptom indicative of PCOS selected from the group consisting of insulin resistance, hyperinsulinemia, hypertension, hyperlipidemia, anovulation or irregular ovulation, infertility, hyperandrogenism, hirsutism, alopecia, acne, hypertrophy multifollicular ovaries, abnormal uterine bleeding and spontaneous abortions.